Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17875688 | 0.77 | NQO2 (0.45) | CYP1A2CYP2C19HTTCCNB2CDK1 | |
| SCHEMBL18635306 | 0.77 | GSK3A (0.38) | HTTCCNB2CDK1CCNB1GSK3A | |
| SCHEMBL18260115 | 0.75 | NQO2 (0.47) | CYP1A2CYP2C19HTTNQO2 | |
| SCHEMBL26650681 | 0.74 | CYP1A2 (0.35) | CYP1A2CYP2C19HTTCCNB2CDK1 | |
| SCHEMBL16039310 | 0.74 | NSD1 (0.39) | CYP1A2CYP2C19HTTCCNB2CDK1 | |
| SCHEMBL18228037 | 0.74 | CYP1A2 (0.35) | CYP1A2CYP2C19HTTCCNB2CDK1 | |
| SCHEMBL3922704 | 0.74 | NQO2 (0.48) | CYP1A2CYP2C19HTTCCNB2CDK1 | |
| SCHEMBL25261769 | 0.71 | ALDH1A1 (0.39) | NQO2ALDH1A1 | |
| SCHEMBL25299656 | 0.71 | ALDH1A1 (0.39) | NQO2ALDH1A1 | |
| SCHEMBL25841003 | 0.71 | PTGES (0.33) | NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101436-A1 | APTAMERS AND SMALL MOLECULE LIGANDS | MeiraGTx Gene Regulation Limited (GB) | 2025-03-27 | — | — | US | disclosed |
| EP-4448769-A2 | APTAMERS AND SMALL MOLECULE LIGANDS | Meiragtx UK II Limited (GB) | 2024-10-23 | — | — | EP | disclosed |
| CN-118786217-A | Aptamer and small molecule ligand | 梅里特斯英国第二有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2023111686-A2 | APTAMERS AND SMALL MOLECULE LIGANDS | MEIRAGTX UK II LIMITED (GB) | 2023-06-22 | — | — | WO | disclosed |
| EP-4188542-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | Global Blood Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022031735-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | PKM, PDK1, PDK2 | CYP1A2 3978/4885CYP2C19 3253/4885HTT 1637/4885 |
| US-20250101436-A1 | APTAMERS AND SMALL MOLECULE LIGANDS | RNGTT, SLIRP, SNRPE | CYP1A2 4582/4885CYP2C19 4705/4885HTT 2184/4885 |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | CYP1A2 53/4885CYP2C19 44/4885HTT 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.